{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:23:44Z","timestamp":1794353024665,"version":"4.9.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Interleukin-17A (IL17A) is a proinflammatory cytokine critically involved in autoimmune diseases, and monoclonal antibodies of IL17A have been approved for clinical treatment of psoriasis. However, a usable psoriatic animal model has been always required for preclinical evaluation of IL17A antagonists. Imiquimod (IMQ)-induced psoriasis model is widely used in fundamental research, but it\u2019s not able to accurately show anti-psoriatic effect of IL17A antagonists with conventional modelling condition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>On female C57BL\/6 mice, with optimization on the usage of IMQ, positive control reagent and anti-mIL17A antibody, a 7-day model with proper testing window, acceptable disease severity as well as high repeatability was developed, and the efficacy of IL17A antagonist can be objectively evaluated by several qualitative and quantitative indices. Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment. In further study, we revealed that IL17A was transient induced by IMQ and directly caused downstream signaling activation. This finding on the kinetical change of IL17A signaling will manifest the pharmacokinetics-pharmacodynamics investigation of IL17A antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A\u2019s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-021-00401-3","type":"journal-article","created":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T13:03:30Z","timestamp":1611839010000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist"],"prefix":"10.1186","volume":"22","author":[{"given":"Qingran","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shidong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,28]]},"reference":[{"key":"401_CR1","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrd3794","volume":"10","author":"P Miossec","year":"2012","unstructured":"Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012;10:763\u201376.","journal-title":"Nat Rev Drug Discov"},{"key":"401_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/ni.3726","volume":"6","author":"PH Papotto","year":"2017","unstructured":"Papotto PH, Ribot JC, Silva-Santos B. IL-17(+) gammadelta T cells as kick-starters of inflammation. Nat Immunol. 2017;6:604\u201311.","journal-title":"Nat Immunol"},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/ni.3742","volume":"6","author":"M Veldhoen","year":"2017","unstructured":"Veldhoen M. Interleukin 17 is a chief orchestrator of immunity. Nat Immunol. 2017;6:612\u201321.","journal-title":"Nat Immunol"},{"key":"401_CR4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nri3707","volume":"9","author":"SL Gaffen","year":"2014","unstructured":"Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;9:585\u2013600.","journal-title":"Nat Rev Immunol"},{"key":"401_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.tips.2008.11.004","volume":"2","author":"S Ivanov","year":"2009","unstructured":"Ivanov S, Linden A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci. 2009;2:95\u2013103.","journal-title":"Trends Pharmacol Sci"},{"key":"401_CR6","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1177\/1060028018799982","volume":"3","author":"SK Shelton","year":"2019","unstructured":"Shelton SK, Bai SR, Jordan JK, Sheehan AH. Ixekizumab: a review of its use for the Management of Moderate to severe plaque psoriasis. Ann Pharmacother. 2019;3:276\u201384.","journal-title":"Ann Pharmacother"},{"key":"401_CR7","doi-asserted-by":"publisher","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","volume":"72","author":"DD Patel","year":"2013","unstructured":"Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013;72:ii116\u201323.","journal-title":"Ann Rheum Dis"},{"key":"401_CR8","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, et al. Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","journal-title":"J Immunol Res"},{"key":"401_CR9","doi-asserted-by":"publisher","unstructured":"Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.\u00a0https:\/\/doi.org\/10.1038\/nrdp.2016.82.","DOI":"10.1038\/nrdp.2016.82"},{"key":"401_CR10","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/exd.13467","volume":"2","author":"JG Krueger","year":"2018","unstructured":"Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;2:115\u201323.","journal-title":"Exp Dermatol"},{"key":"401_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"3","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;3:379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"401_CR12","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1080\/21645515.2017.1356498","volume":"10","author":"C Jeon","year":"2017","unstructured":"Jeon C, Sekhon S, Yan D, et al. Monoclonal antibodies inhibiting IL-12, \u221223, and \u221217 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;10:2247\u201359.","journal-title":"Hum Vaccin Immunother"},{"issue":"12","key":"401_CR13","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.3390\/ijms18122514","volume":"18","author":"K Bochenska","year":"2017","unstructured":"Bochenska K, Smolinska E, Moskot M, Jakobkiewicz-Banecka J, Gabig-Ciminska M. Models in the research process of psoriasis. Int J Mol Sci. 2017;18(12):2514.","journal-title":"Int J Mol Sci"},{"key":"401_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/1346-8138.14112","volume":"3","author":"K Nakajima","year":"2018","unstructured":"Nakajima K, Sano S. Mouse models of psoriasis and their relevance. J Dermatol. 2018;3:252\u201363.","journal-title":"J Dermatol"},{"key":"401_CR15","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1080\/17460441.2018.1463214","volume":"6","author":"SY Chuang","year":"2018","unstructured":"Chuang SY, Lin CH, Sung CT, Fang JY. Murine models of psoriasis and their usefulness for drug discovery. Expert Opin Drug Discov. 2018;6:551\u201362.","journal-title":"Expert Opin Drug Discov"},{"key":"401_CR16","first-page":"1749803","volume":"2019","author":"J Wu","year":"2019","unstructured":"Wu J, Li S, Li T, et al. pDC activation by TLR7\/8 ligand CL097 compared to TLR7 ligand IMQ or TLR9 ligand CpG. J Immunol Res. 2019;2019:1749803.","journal-title":"J Immunol Res"},{"key":"401_CR17","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2340\/00015555-3086","volume":"3","author":"T Hashimoto","year":"2019","unstructured":"Hashimoto T, Sakai K, Sanders KM, Yosipovitch G, Akiyama T. Antipruritic effects of Janus kinase inhibitor Tofacitinib in a mouse model of psoriasis. Acta Derm Venereol. 2019;3:298\u2013303.","journal-title":"Acta Derm Venereol"},{"key":"401_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13073-017-0415-3","volume":"1","author":"WR Swindell","year":"2017","unstructured":"Swindell WR, Michaels KA, Sutter AJ, et al. Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. Genome Med. 2017;1:24.","journal-title":"Genome Med"},{"key":"401_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/jid.2012.318","volume":"2","author":"K El Malki","year":"2013","unstructured":"El Malki K, Karbach SH, Huppert J, et al. An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling. J Investig Dermatol. 2013;2:441\u201351.","journal-title":"J Investig Dermatol"},{"key":"401_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/exd.13484","volume":"2","author":"Y Higashi","year":"2018","unstructured":"Higashi Y, Yamakuchi M, Fukushige T, et al. High-fat diet exacerbates imiquimod-induced psoriasis-like dermatitis in mice. Exp Dermatol. 2018;2:178\u201384.","journal-title":"Exp Dermatol"},{"key":"401_CR21","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaci.2017.07.033","volume":"3","author":"N Kusuba","year":"2018","unstructured":"Kusuba N, Kitoh A, Dainichi T, et al. Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue. J Allergy Clin Immunol. 2018;3:972\u201381 e10.","journal-title":"J Allergy Clin Immunol"},{"key":"401_CR22","doi-asserted-by":"publisher","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","volume":"9","author":"L van der Fits","year":"2009","unstructured":"van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis. J Immunol. 2009;9:5836\u201345.","journal-title":"J Immunol"},{"issue":"36","key":"401_CR23","doi-asserted-by":"publisher","first-page":"eaau9657","DOI":"10.1126\/sciimmunol.aau9657","volume":"4","author":"Y Su","year":"2019","unstructured":"Su Y, Huang J, Zhao X, et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019;4(36):eaau9657.","journal-title":"Sci Immunol"},{"key":"401_CR24","doi-asserted-by":"publisher","first-page":"6756138","DOI":"10.1155\/2016\/6756138","volume":"2016","author":"P Alvarez","year":"2016","unstructured":"Alvarez P, Jensen LE. Imiquimod treatment causes systemic disease in mice resembling generalized Pustular psoriasis in an IL-1 and IL-36 dependent manner. Mediat Inflamm. 2016;2016:6756138.","journal-title":"Mediat Inflamm"},{"key":"401_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.cellsig.2017.02.014","volume":"33","author":"A Nadeem","year":"2017","unstructured":"Nadeem A, Ahmad SF, Al-Harbi NO, et al. GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model. Cell Signal. 2017;33:59\u201368.","journal-title":"Cell Signal"},{"key":"401_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1124\/jpet.115.224246","volume":"2","author":"PR Mangan","year":"2015","unstructured":"Mangan PR, Su LJ, Jenny V, et al. Dual inhibition of Interleukin-23 and Interleukin-17 offers superior efficacy in mouse models of autoimmunity. J Pharmacol Exp Ther. 2015;2:152\u201365.","journal-title":"J Pharmacol Exp Ther"},{"key":"401_CR27","first-page":"7052560","volume":"2017","author":"SJ Kim","year":"2017","unstructured":"Kim SJ, Jang YW, Hyung KE, et al. Therapeutic effects of methanol extract from Euphorbia kansui Radix on Imiquimod-induced psoriasis. J Immunol Res. 2017;2017:7052560.","journal-title":"J Immunol Res"},{"key":"401_CR28","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1002\/cpim.71","volume":"1","author":"TP Singh","year":"2019","unstructured":"Singh TP, Zhang HH, Hwang ST, Farber JM. IL-23- and Imiquimod-induced models of experimental psoriasis in mice. Curr Protoc Immunol. 2019;1:e71.","journal-title":"Curr Protoc Immunol"},{"key":"401_CR29","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00403-010-1033-8","volume":"7","author":"S Fujishima","year":"2010","unstructured":"Fujishima S, Watanabe H, Kawaguchi M, et al. Involvement of IL-17F via the induction of IL-6 in psoriasis. Archives for Dermatological Research. Arch Dermatol Forsch. 2010;7:499\u2013505.","journal-title":"Arch Dermatol Forsch"},{"key":"401_CR30","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/jid.2013.404","volume":"3","author":"AL Croxford","year":"2014","unstructured":"Croxford AL, Karbach S, Kurschus FC, et al. IL-6 regulates neutrophil microabscess formation in IL-17A-driven psoriasiform lesions. J Investig Dermatol. 2014;3:728\u201335.","journal-title":"J Investig Dermatol"},{"key":"401_CR31","first-page":"1143","volume":"12","author":"C Jacquin-Porretaz","year":"2019","unstructured":"Jacquin-Porretaz C, Cordonnier M, Nardin C, et al. Increased levels of interleukin-17A Exosomes in psoriasis. Acta Derm Venereol. 2019;12:1143\u20137.","journal-title":"Acta Derm Venereol"},{"key":"401_CR32","doi-asserted-by":"publisher","first-page":"485","DOI":"10.5021\/ad.2018.30.4.485","volume":"4","author":"M Madsen","year":"2018","unstructured":"Madsen M, Pedersen TX, Nielsen LB, Johansen C, Hansen PR. Differential effects of digoxin on Imiquimod-induced psoriasis-like skin inflammation on the ear and Back. Ann Dermatol. 2018;4:485\u20138.","journal-title":"Ann Dermatol"},{"key":"401_CR33","doi-asserted-by":"publisher","first-page":"4953","DOI":"10.4049\/jimmunol.1500551","volume":"10","author":"D Terhorst","year":"2015","unstructured":"Terhorst D, Chelbi R, Wohn C, et al. Dynamics and Transcriptomics of skin dendritic cells and macrophages in an Imiquimod-induced, biphasic mouse model of psoriasis. J Immunol. 2015;10:4953\u201361.","journal-title":"J Immunol"},{"key":"401_CR34","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.biopha.2018.10.062","volume":"109","author":"Y Li","year":"2019","unstructured":"Li Y, Zhang G, Chen M, et al. Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-kappaB and TLR7 pathways in mice. Biomed Pharmacother. 2019;109:1876\u201383.","journal-title":"Biomed Pharmacother"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12865-021-00401-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-021-00401-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T01:41:20Z","timestamp":1611884480000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-021-00401-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,28]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1186\/s12865-021-00401-3","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,28]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal related protocols were reviewed and approved by Animal Welfare Ethics Committee of Hitgen Inc., and all methods were carried out in accordance with relevant guidelines and regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employed by HitGen Inc., the research and authorship of this article was completed within the scope of authors\u2019 employment with HitGen Inc. The authors declared no other potential conflicts of interest exist.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11"}}